z-logo
open-access-imgOpen Access
The role of PD-1/PD-L1 inhibitors in the treatment for non-small cell lung cancer (NSCLC)
Author(s) -
Li Che,
Manyi Xu
Publication year - 2022
Publication title -
highlights in science engineering and technology
Language(s) - English
Resource type - Journals
ISSN - 2791-0210
DOI - 10.54097/hset.v8i.1108
Subject(s) - durvalumab , atezolizumab , pembrolizumab , nivolumab , avelumab , pd l1 , non small cell lung cancer (nsclc) , medicine , lung cancer , oncology , immunotherapy , chemotherapy , cancer research , cancer , a549 cell

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom